Skip to content
Inciteful Med

Validation & Orientation: Understanding Your Scleroderma Diagnosis

Last updated:

Scleroderma is a rare, highly variable autoimmune condition. The most important first step after diagnosis is identifying whether you have localized scleroderma or systemic sclerosis, and seeking care from a specialized rheumatologist who can monitor for internal organ involvement.

Key Takeaways

  • • Scleroderma is a highly variable disease, meaning it affects every person differently and is not a one-size-fits-all condition.
  • • There are two main types: localized scleroderma (morphea) which primarily affects the skin, and systemic sclerosis which can affect internal organs.
  • • The disease is driven by a combination of blood vessel damage, an overactive immune system, and excess collagen production (fibrosis).
  • • Seeking care from a rheumatologist at a specialized Scleroderma Center significantly improves outcomes by catching complications early.
  • • Treatments are advancing rapidly, with new medications available to manage the immune system and protect organ health.

Receiving a diagnosis of scleroderma often brings a wave of “information overload” alongside genuine fear. Because this is a rare disease (an orphan disease), you may find that even your primary care doctor has limited experience with it [1][2]. It is completely normal to feel overwhelmed, but understanding the basic facts can help you regain a sense of control.

Three Stabilizing Facts

In the early days of a diagnosis, it is easy to find outdated or frightening information online. Here are three modern, research-backed truths to help ground you:

  1. You are not a statistic. While scleroderma is serious, it is highly heterogeneous (variable). This means the disease looks different in every person. Many people live long, productive lives by managing specific symptoms and monitoring organ health [3][4].
  2. Specialized care makes a difference. Research shows that patients who are treated at specialized Scleroderma Centers often have better outcomes because these teams are experts in catching and treating complications early [2][5].
  3. Treatment is advancing rapidly. We are no longer in an era where “nothing can be done.” From advanced immunosuppressants (medications that quiet the immune system) to new drugs specifically for lung health, doctors have more tools than ever before to slow the disease [6][7].

Understanding the Two Main Types

“Scleroderma” is an umbrella term for several conditions. It is vital to know which type you have, as the treatment and outlook are very different. You can read more in our Subtypes & Autoantibodies guide.

  • Localized Scleroderma (Morphea): This type is usually confined to the skin and the tissue directly underneath it. It occurs in about 0.4 to 2.7 people per 100,000 [8]. While it can cause skin discoloration or hardening, it typically does not affect internal organs like the heart or lungs [9].
  • Systemic Sclerosis (SSc): This is the systemic form of the disease, with approximately 19.3 new cases per million diagnosed in the U.S. annually [10]. It can involve the skin as well as internal organs (such as the lungs, gastrointestinal tract, and kidneys) [11].

How the Disease Works: The Pathologic Triad

Researchers describe the “engine” of systemic sclerosis as a triad of three overlapping processes [12][13]. You can learn more about this in our Biology & Mimics section:

  • Vascular Damage (Vasculopathy): Often the earliest sign, this involves damage to small blood vessels. This is why many patients experience Raynaud’s phenomenon—where fingers turn white, blue, or red in response to cold or stress [14][15].
  • Immune Activation: Your immune system becomes overactive and begins attacking the body’s own tissues. This “dysregulation” triggers the production of autoantibodies (proteins that attack the self), which doctors use to help predict how the disease might progress [16][17].
  • Tissue Fibrosis: In response to the vessel damage and immune activity, the body produces too much collagen. This leads to fibrosis (scarring), which causes the skin to tighten and can affect the function of internal organs [18][12].

Why Rarity Matters for Your Care

Because systemic sclerosis is rare, many local doctors may only see one or two cases in their entire career [19]. This can lead to delays in diagnosis or a lack of familiarity with “red flag” complications like Scleroderma Renal Crisis (a sudden, dangerous rise in blood pressure) or Interstitial Lung Disease (scarring of the lungs) [20][21].

Being your own advocate means seeking out a specialist—usually a rheumatologist—who focuses specifically on scleroderma [22]. If you need a referral, try using this script with your primary care doctor: “Because scleroderma is a complex and rare systemic disease, I would like to be referred to a specialized Scleroderma Center or a rheumatologist with extensive experience in this condition to manage my long-term care.” You can read more about finding the right doctor in Building Your Care Team.

Frequently Asked Questions

What is the difference between localized scleroderma and systemic sclerosis?
Localized scleroderma, also known as morphea, typically only affects the skin and the tissue directly underneath it. Systemic sclerosis is a more widespread form that involves the skin as well as internal organs like the lungs, heart, gastrointestinal tract, and kidneys.
Why is it important to see a scleroderma specialist?
Because scleroderma is a rare and highly variable disease, many local doctors may not have much experience with it. Specialists at dedicated Scleroderma Centers are experts at catching dangerous complications early and offering advanced treatments to slow the disease.
What causes the skin tightening in scleroderma?
The skin tightening is caused by fibrosis, or scarring. This happens when the immune system becomes overactive and triggers the body to produce too much collagen, which builds up in the skin and tissues.
What is Raynaud's phenomenon?
Raynaud's phenomenon is often one of the earliest signs of systemic sclerosis. It occurs when small blood vessels are damaged, causing your fingers or toes to turn white, blue, or red in response to cold temperatures or emotional stress.
What baseline tests do I need after a scleroderma diagnosis?
After a diagnosis, your doctor will likely order blood tests to check for specific autoantibodies, which help predict how the disease might progress. You will also need baseline tests to evaluate the health of your heart, lungs, and kidneys.

Questions for Your Doctor

  • • Based on my blood work and skin symptoms, do I have localized scleroderma or systemic sclerosis?
  • • Which specific autoantibodies (like anti-Scl-70, anti-centromere, or anti-RNA polymerase III) were found in my tests, and what do they tell us about my risk for lung or kidney involvement?
  • • How many patients with scleroderma do you currently treat, and should I also be seen at a specialized Scleroderma Center?
  • • What baseline tests do I need right now to check my heart, lungs, and kidneys?
  • • What are the early 'red flag' symptoms I should watch for that would require an immediate call to your office?

Questions for You

  • • When did you first notice your fingers changing color in the cold (Raynaud's phenomenon), and how has that changed over time?
  • • Have you noticed any new or worsening shortness of breath during daily activities like walking or climbing stairs?
  • • Are you able to monitor your blood pressure at home, and do you have a way to track those numbers for your doctor?
  • • What are your biggest fears or concerns about this diagnosis that you want to make sure your care team addresses?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.

    Namas R, Elarabi M, Khan S, et al.

    Journal of scleroderma and related disorders 2023; (8(2)):137-150 doi:10.1177/23971983221145788.

    PMID: 37287950
  2. 2

    New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine.

    Lescoat A, Varga J, Matucci-Cerinic M, Khanna D

    Expert opinion on investigational drugs 2021; (30(6)):635-652 doi:10.1080/13543784.2021.1923693.

    PMID: 33909517
  3. 3

    What have we learned about systemic sclerosis from the EUSTAR database?

    Campochiaro C, Vonk MC, Osborne T, et al.

    Current opinion in rheumatology 2026; (38(1)):53-59 doi:10.1097/BOR.0000000000001128.

    PMID: 40965427
  4. 4

    Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes.

    Lescoat A, Murphy SL, Roofeh D, et al.

    Journal of scleroderma and related disorders 2021; (6(1)):66-76 doi:10.1177/2397198320961967.

    PMID: 34316516
  5. 5

    Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry.

    Shanmugam VK, Frech TM, Steen VD, et al.

    Clinical rheumatology 2020; (39(1)):93-102 doi:10.1007/s10067-019-04792-y.

    PMID: 31667644
  6. 6

    Frequency and determinants of use of immunosuppressants in the Australian Scleroderma Cohort Study.

    Fairley JL, Hansen D, Proudman S, et al.

    Journal of scleroderma and related disorders 2025; 23971983251342690 doi:10.1177/23971983251342690.

    PMID: 40416409
  7. 7

    Autologous stem cell transplantation in scleroderma.

    Farge D, Ait Abdallah N, Marjanovic Z, Del Papa N

    Presse medicale (Paris, France : 1983) 2021; (50(1)):104065 doi:10.1016/j.lpm.2021.104065.

    PMID: 33548374
  8. 8

    Upcoming treatments for morphea.

    Wenzel D, Haddadi NS, Afshari K, et al.

    Immunity, inflammation and disease 2021; (9(4)):1101-1145 doi:10.1002/iid3.475.

    PMID: 34272836
  9. 9

    Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

    Zhao M, Wu J, Wu H, et al.

    Clinical reviews in allergy & immunology 2022; (62(2)):273-291 doi:10.1007/s12016-020-08831-4.

    PMID: 33449302
  10. 10

    Gastrointestinal involvement in systemic sclerosis: An updated review.

    Nassar M, Ghernautan V, Nso N, et al.

    Medicine 2022; (101(45)):e31780 doi:10.1097/MD.0000000000031780.

    PMID: 36397401
  11. 11

    Cardio-pulmonary involvement in systemic sclerosis: A study at a tertiary care center.

    Arakkal G, Chintagunta SR, Chandika V, et al.

    Indian journal of dermatology, venereology and leprology 2017; (83(6)):677-682 doi:10.4103/0378-6323.198453.

    PMID: 29035287
  12. 12

    Interferon-γ Induces Interleukin-6 Production and Alpha-smooth Muscle Actin Expression in Systemic Sclerosis Fibroblasts.

    Rokni M, Farhadi E, Kavosi H, et al.

    Iranian journal of allergy, asthma, and immunology 2024; (23(2)):197-220 doi:10.18502/ijaai.v23i2.15325.

    PMID: 38822514
  13. 13

    Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment.

    Sundblad V, Gomez RA, Stupirski JC, et al.

    Frontiers in pharmacology 2021; (12()):650605 doi:10.3389/fphar.2021.650605.

    PMID: 33959016
  14. 14

    Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.

    Dave J, Mahajan S, Khadilkar P, Pradhan V

    The Journal of the Association of Physicians of India 2022; (70(11)):11-12 doi:10.5005/japi-11001-0136.

    PMID: 37355940
  15. 15

    Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India.

    Poonia K, Bhalla M, Dogar K, et al.

    Clinical rheumatology 2023; (42(7)):1827-1832 doi:10.1007/s10067-023-06562-3.

    PMID: 36897457
  16. 16

    Serum type I interferon score as a disease activity biomarker in patients with diffuse cutaneous systemic sclerosis: a retrospective cohort study.

    Hinchcliff M, Khanna D, De Lorenzis E, et al.

    The Lancet. Rheumatology 2025; (7(6)):e403-e414 doi:10.1016/S2665-9913(24)00403-X.

    PMID: 40179922
  17. 17

    Nuclear-penetrating scleroderma autoantibody inhibits topoisomerase 1 cleavage complex formation.

    May CK, Noble PW, Herzog EL, et al.

    Biochemical and biophysical research communications 2024; (720()):150123 doi:10.1016/j.bbrc.2024.150123.

    PMID: 38759301
  18. 18

    Multimodal analyses of early, untreated systemic sclerosis skin identify a proinflammatory vascular niche of macrophage-fibroblast signaling.

    Jarnagin HC, Parvizi R, Gong Z, et al.

    JCI insight 2026; (11(3)).

    PMID: 41411065
  19. 19

    Caring for the Patient With Limited Systemic Scleroderma.

    Lachner KD

    Orthopedic nursing 2016; (35(1)):5-10; quiz 11-2 doi:10.1097/NOR.0000000000000212.

    PMID: 26814000
  20. 20

    Patient perception of disease burden in diffuse cutaneous systemic sclerosis.

    Khanna D, Allanore Y, Denton CP, et al.

    Journal of scleroderma and related disorders 2020; (5(1)):66-76 doi:10.1177/2397198319866615.

    PMID: 35382406
  21. 21

    Systemic Sclerosis and Pulmonary Disease.

    Ngo K

    Advances in experimental medicine and biology 2021; (1303()):173-182 doi:10.1007/978-3-030-63046-1_10.

    PMID: 33788193
  22. 22

    Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives.

    Stubbs LA, Ferry AM, Guffey D, et al.

    Pediatric rheumatology online journal 2023; (21(1)):39 doi:10.1186/s12969-023-00819-6.

    PMID: 37098622

This page provides a general orientation to a scleroderma diagnosis for educational purposes. Always consult a specialized rheumatologist to discuss your specific subtype and treatment plan.

Stay up to date

Get notified when new research about Scleroderma is published.

No spam. Unsubscribe anytime.